Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) was the recipient of a significant decline in short interest in September. As of September 30th, there was short interest totalling 7,230,000 shares, a decline of 11.7% from the September 15th total of 8,190,000 shares. Based on an average trading volume of 423,100 shares, the days-to-cover ratio is currently 17.1 days. Approximately 19.9% of the company’s stock are short sold.
Apogee Therapeutics Trading Down 2.0 %
Shares of APGE opened at $55.81 on Tuesday. Apogee Therapeutics has a 12 month low of $14.19 and a 12 month high of $72.29. The stock has a fifty day moving average price of $50.78 and a 200-day moving average price of $48.74. The firm has a market cap of $3.26 billion, a PE ratio of -10.63 and a beta of 2.75.
Apogee Therapeutics (NASDAQ:APGE – Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.60) EPS for the quarter, hitting analysts’ consensus estimates of ($0.60). As a group, research analysts forecast that Apogee Therapeutics will post -2.57 EPS for the current year.
Insider Activity at Apogee Therapeutics
Institutional Investors Weigh In On Apogee Therapeutics
A number of large investors have recently bought and sold shares of the company. Handelsbanken Fonder AB lifted its stake in Apogee Therapeutics by 25.7% during the 3rd quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company’s stock valued at $517,000 after acquiring an additional 1,800 shares during the period. SG Americas Securities LLC purchased a new stake in Apogee Therapeutics in the third quarter valued at $475,000. Perceptive Advisors LLC grew its position in Apogee Therapeutics by 2.2% during the 2nd quarter. Perceptive Advisors LLC now owns 2,105,636 shares of the company’s stock worth $82,857,000 after purchasing an additional 45,241 shares during the period. Driehaus Capital Management LLC raised its stake in shares of Apogee Therapeutics by 2.6% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,117,870 shares of the company’s stock valued at $83,338,000 after buying an additional 54,107 shares during the last quarter. Finally, Dark Forest Capital Management LP lifted its holdings in shares of Apogee Therapeutics by 78.3% in the 2nd quarter. Dark Forest Capital Management LP now owns 14,083 shares of the company’s stock valued at $554,000 after buying an additional 6,186 shares during the period. Hedge funds and other institutional investors own 79.04% of the company’s stock.
About Apogee Therapeutics
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Further Reading
- Five stocks we like better than Apogee Therapeutics
- What Are the U.K. Market Holidays? How to Invest and Trade
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- Most Volatile Stocks, What Investors Need to Know
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.